Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PLX647 是具有口服活性的、高效的、特异性的FMS 和KIT 双激酶抑制剂,IC50分别为 28 和 16 nM。它 (1 μM) 在 400 个激酶组中显示出对 FMS 和 KIT 有选择性,但 FLT3 和 KDR 除外 (IC50=91 和 130 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 295 | 5日内发货 | ||
5 mg | ¥ 497 | 5日内发货 | ||
10 mg | ¥ 814 | 5日内发货 | ||
1 mL * 10 mM (in DMSO) | ¥ 547 | 5日内发货 |
产品描述 | PLX647 is a highly selective dual FMS/KIT kinase inhibitor (IC50: 28/16 nM). |
靶点活性 | c-Kit:16 nM, FMS:28nM |
激酶实验 | HTS screen: To start an assay, 0.5 μL of 5 mg/mL test compound (about 50 μM final reaction concentration) or DMSO control is aliquoted into each well. Both enzyme and substrate are prepared in UCH reaction buffer (50 mM Tris-HCl [pH 7.6], 0.5 mM EDTA, 5 mM DTT, and 0.5 mg/mL ovalbumin). 25 μL of 0.6 nM UCH-L1 is then added to each well except substrate control wells, followed by plate shaking for 45–60 s on an automatic shaker. The enzyme/compound mixture is incubated at room temperature for 30 min before 25 μL of 200 nM Ub-AMC is added to initiate the enzyme reaction. The reaction mixture (300 pM UCH-L1, 100 nM Ubiquitin-AMC with 2.5 μg test compound) is incubated at room temperature for 30 additional minutes prior to quenching the reaction by the addition of 10 μL 500 mM acetic acid per well. The fluorescence emission intensity is measured on a LJL Analyst using a coumarin filter set (ex = 365 nm, em = 450 nm) and is subtracted by the intrinsic compound fluorescence to reveal the enzyme activity. A DMSO control (0.5 μL of DMSO, 25 μL of UCH-L1, 25 μL of ubiquitin-AMC, 10 μL of acetic acid), enzyme control (25 μL of UCH-L1, 25 μL of buffer, 10 μL of acetic acid), substrate control (25 μL of buffer, 25 μL of ubiquitin-AMC, 10 μL of acetic acid), and inhibitor control (0.5 μL of ubiquitin aldehyde [100 nM stock], 25 μL of UCH-L1, 25 μL of ubiquitin-AMC, 10 μL of acetic acid) are also performed in each assay plate to ensure quality and reproducibility. Potential UCH-L1 inhibitors are selected if the compounds demonstrated greater than 60% inhibition compared to the controls. The UCH-L1 enzymatic reactions are manually repeated twice using the same protocol to confirm the results for the hit compounds from the primary robot-assisted screen. |
分子量 | 382.38 |
分子式 | C21H17F3N4 |
CAS No. | 873786-09-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 31 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PLX647 873786-09-5 Tyrosine Kinase/Adaptors c-Fms c-Kit Inhibitor cells osteoclast SCFR BCR-FMS CD117 bone PLX-647 differentiation colony stimulating factor 1 receptor BCR-KIT PLX 647 CSF1R inhibit CSF-1 receptor proliferation CSF-1R inhibitor